Details of the Drug

General Information of Drug (ID: DMVEK07)

• Drug Name: Magnesium Sulfate
• Synonyms: Magnesiumsulfat; Bitter salt; Epsom salt; Hair salt; Heptahydrate Magnesium Sulfate; Kieserite [as monohydrate]; Magnesium Sulfate In Plastic Container; Magnesium Sulphate Hydrate; Magnesium bisulfate; Magnesium hydrogensulphate; Magnesium sulfate anhydrous; Magnesium sulfate dried; Magnesium sulfate hexahydrate; Magnesium sulfate solution; Magnesium sulphate; Sal Angalis; Sal De sedlitz; Sal amarum; Sal anglicum; Sal catharticum; Sal seidlitense; Salts of england; Sulfuric acid magnesium salt; Tomix OT; MgSO4; Epsom Sa (TN); Magnesium Sulfate, Heptahydrate; Magnesium sulfate in dextrose 5% in plastic container; Magnesium(II) sulfate; OT-S; Sel d'angleterre; Sulfate, Magnesium; Sulfuric acid magnesium salt (VAN); Sulfuric acid, magnesium salt; Magnesium sulfate (1:1); Magnesium(2+) ion sulfate; OT-S (drying agent); SDA 15-062-07; Sulfuric acid magnesium salt (1:1); Sulfuric acid, C10-16 alkyl ester, magnesium salt; Sulfuric acid, magnesium salt (1:1); Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts; (C10-C16) Alkylalcohol sulfuric acid, magnesium salt

Indication

Disease Entry	ICD 11	Status	REF
Acute pain	MG31	Approved	[1]
Familial primary hypomagnesemia	N.A.	Approved	[2]
Hypertension, pregnancy-induced	N.A.	Approved	[2]
Mild pre-eclampsia	N.A.	Approved	[2]
Non-arteritic anterior ischemic optic neuropathy	9C40.40	Approved	[2]
Pain	MG30-MG3Z	Approved	[2]
Severe pre-eclampsia	N.A.	Approved	[2]
Traumatic brain injury	NA07.Z	Approved	[2]

• Therapeutic Class: Analgesics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight; 120.37
  Logarithm of the Partition Coefficient; Not Available
  Rotatable Bond Count; 0
  Hydrogen Bond Donor Count; 0
  Hydrogen Bond Acceptor Count; 4
• ADMET Property: Half-life: The concentration or amount of drug in body reduced by one-half in 43.2 hours (in newborns) [3]
• Chemical Identifiers:
  Formula: MgO4S
  IUPAC Name: magnesium;sulfate
  Canonical SMILES: [O-]S(=O)(=O)[O-].[Mg+2]
  InChI: InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
  InChIKey: CSNNHWWHGAXBCP-UHFFFAOYSA-L
• Cross-matching ID:
  PubChem CID: 24083
  ChEBI ID: CHEBI:32599
  CAS Number: 7487-88-9
  DrugBank ID: DB00653
  TTD ID: D02LDN
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Antagonist	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[5]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[5]
Kallikrein-8 (KLK8)	OTGVGHXY	KLK8_HUMAN	Gene/Protein Processing	[6]
Renin (REN)	OT52GZR2	RENI_HUMAN	Gene/Protein Processing	[7]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Magnesium Sulfate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sarecycline	DMLZNIQ	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Sarecycline .	Acne vulgaris [ED80]	[8]
Framycetin	DMF8DNE	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Framycetin.	Alcoholic liver disease [DB94]	[9]
Nifedipine	DMSVOZT	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Nifedipine.	Angina pectoris [BA40]	[10]
Ofloxacin	DM0VQN3	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Kanamycin	DM2DMPO	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Kanamycin.	Bacterial infection [1A00-1C4Z]	[9]
Trovafloxacin	DM6AN32	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Sparfloxacin	DMB4HCT	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Streptomycin	DME1LQN	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Streptomycin.	Bacterial infection [1A00-1C4Z]	[9]
Gemifloxacin	DMHT34O	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Norfloxacin	DMIZ6W2	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[11]
ABT-492	DMJFD2I	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[11]
Gentamicin	DMKINJO	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Gentamicin.	Bacterial infection [1A00-1C4Z]	[9]
Omadacycline	DMR2J95	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Omadacycline.	Bacterial infection [1A00-1C4Z]	[8]
Netilmicin	DMRD1QK	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Netilmicin.	Bacterial infection [1A00-1C4Z]	[9]
Levofloxacin	DMS60RB	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Tobramycin	DMUI0CH	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Tobramycin.	Bacterial infection [1A00-1C4Z]	[9]
Minocycline	DMVN5OH	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Minocycline.	Bacterial infection [1A00-1C4Z]	[8]
Lomefloxacin	DMVRH9C	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Tetracycline	DMZA017	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Tetracycline.	Bacterial infection [1A00-1C4Z]	[8]
Etidronic acid	DM1XHYJ	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Etidronic acid.	Bone paget disease [FB85]	[12]
Risedronate	DM5FLTY	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Risedronate.	Bone paget disease [FB85]	[13]
Doxercalciferol	DM6FG1P	Moderate	Increased risk of hypermagnesemia by the combination of Magnesium Sulfate and Doxercalciferol.	Chronic kidney disease [GB61]	[14]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Atracurium.	Corneal disease [9A76-9A78]	[15]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Mivacurium.	Corneal disease [9A76-9A78]	[15]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Pancuronium.	Corneal disease [9A76-9A78]	[15]
Dolutegravir	DMCZGRE	Major	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Dolutegravir.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Raltegravir	DMYURI6	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Raltegravir.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Paricalcitol	DMYBV3G	Moderate	Increased risk of hypermagnesemia by the combination of Magnesium Sulfate and Paricalcitol.	Hyper-parathyroidism [5A51]	[14]
Levamlodipine	DM92S6N	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Levamlodipine.	Hypertension [BA00-BA04]	[10]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Magnesium Sulfate and Felodipine.	Hypertension [BA00-BA04]	[10]
Clevidipine butyrate	DMW4M97	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Clevidipine butyrate.	Hypertension [BA00-BA04]	[10]
Baloxavir marboxil	DM1UV7F	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Baloxavir marboxil.	Influenza [1E30-1E32]	[18]
Ibandronate	DM0QZBN	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Ibandronate.	Low bone mass disorder [FB83]	[19]
Dihydrotachysterol	DMFB97P	Moderate	Increased risk of hypermagnesemia by the combination of Magnesium Sulfate and Dihydrotachysterol.	Mineral deficiency [5B5K]	[14]
Gatifloxacin	DMSL679	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[11]
Penicillamine	DM40EF6	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Penicillamine.	Rheumatoid arthritis [FA20]	[20]
Deferiprone	DMS2M7O	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Deferiprone.	Thalassaemia [3A50]	[21]
Eltrombopag	DMOGFIX	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Eltrombopag.	Thrombocytopenia [3B64]	[22]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Vecuronium.	Tonus and reflex abnormality [MB47]	[15]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Rocuronium.	Tonus and reflex abnormality [MB47]	[15]
Cinoxacin	DM4EWNS	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Cinoxacin.	Urinary tract infection [GC08]	[11]
Plazomicin	DMKMBES	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Plazomicin.	Urinary tract infection [GC08]	[9]
Nalidixic acid	DMRM0JV	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Nalidixic acid.	Urinary tract infection [GC08]	[23]

References

• [1] Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
• [2] Magnesium Sulfate FDA Label
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
• [5] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [6] Activation and enzymatic characterization of recombinant human kallikrein 8. Biol Chem. 2006 Jun;387(6):723-31. doi: 10.1515/BC.2006.091.
• [7] Haemodynamic and endocrine effects of deliberate hypotension with magnesium sulphate for cerebral-aneurysm surgery. Eur J Anaesthesiol. 1991 Mar;8(2):115-21.
• [8] Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
• [9] Piper BJ, Alinea AA, Wroblewski JR, et al. A Quantitative and Narrative Evaluation of Goodman and Gilman's Pharmacological Basis of Therapeutics. Pharmacy (Basel). 2019;8(1):1. Published 2019 Dec 20. [PMID: 31861770]
• [10] Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
• [11] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
• [12] Product Information. Boniva (ibandronate). Roche Laboratories, Nutley, NJ.
• [13] Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
• [14] Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
• [15] Fuchs-Buder T, Wilder-Smith OH, Borgeat A, Tassonyi E "Interaction of magnesium sulphate with vecuronium-induced neuromuscular block." Br J Anaesth 74 (1995): 405-9. [PMID: 7734259]
• [16] Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
• [17] Canadian Pharmacists Association.
• [18] Product Information. Xofluza (baloxavir marboxil). Genentech, South San Francisco, CA.
• [19] Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54. [PMID: 8845456]
• [20] Haagsma CJ "Clinically important drug interactions with disease-modifying antirheumatic drugs." Drugs Aging 13 (1998): 281-9. [PMID: 9805209]
• [21] Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
• [22] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [23] Product Information. NegGram (nalidixic acid). Sanofi Winthrop Pharmaceuticals, New York, NY.